HannaH Phase III Randomised Study: Association of Total Pathological Complete Response With Event-Free Survival in HER2-Positive Early Breast Cancer Treated With Neoadjuvant-Adjuvant Trastuzumab After 2 Years of Treatment-Free Follow-up

Total pathologic complete response (tpCR) was associated with improved event-free survival, adding to evidence that tpCR is associated with clinical benefit in HER2-positive early breast cancer.

 European Journal of Cancer